Form 4: Sangamo Therapeutics Insider Tax Withholding Transaction

SVP-Chief Development Officer Nathalie Dubois-Stringfellow disposed of 4,036 shares to satisfy mandatory tax obligations.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, Inc., reported a transaction involving 4,036 shares of common stock.
• The transaction occurred on May 25, 2026, at a price of $0.1743 per share.
• The disposal was executed to satisfy mandatory tax withholding requirements related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains a beneficial ownership of 328,733 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative requirement for equity compensation rather than a market-driven trade.

Positives

• The transaction was non-discretionary and strictly for tax compliance purposes, indicating no change in the officer's long-term confidence in the company.

Negatives

• The transaction reflects a reduction in the officer's direct shareholding, albeit for tax purposes.

Risks

• The company's stock price is currently trading at a low valuation of $0.1743 per share, which may reflect ongoing market concerns regarding the company's financial position or clinical pipeline progress.

Future Outlook

The filing notes that 78,750 shares remain subject to vesting in 7 successive equal quarterly installments, contingent upon the reporting person's continued service.

Management Comments

• The transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that mandatory tax withholding transactions are standard practice for biotech executives receiving equity compensation and do not typically signal a change in corporate strategy or insider sentiment.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions for tax obligations is a standard governance practice in the biotechnology sector.
• The low share price of $0.1743 is consistent with the volatility often seen in clinical-stage gene therapy companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and related to tax compliance.

Next Steps

• Continued vesting of remaining 78,750 shares in 7 successive equal quarterly installments.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Insider Trading, Form 4, Biotech, Tax Withholding